Simon M Ametamey
Overview
Explore the profile of Simon M Ametamey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
159
Citations
2289
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haider A, Bengs S, Portmann A, Frohlich S, Etter D, Maredziak M, et al.
Biol Sex Differ
. 2025 Jan;
16(1):2.
PMID: 39819738
Background: Presentations and outcomes of acute myocardial infarction (MI) differ between women and men, with the worst outcomes being reported in younger women. Mental stress induced ischemia and sympathetic activation...
2.
Aebi J, Atz K, Ametamey S, Benz J, Blaising J, Butini S, et al.
Chimia (Aarau)
. 2024 Sep;
78(7-8):499-512.
PMID: 39221845
The endocannabinoid system (ECS) is a critical regulatory network composed of endogenous cannabinoids (eCBs), their synthesizing and degrading enzymes, and associated receptors. It is integral to maintaining homeostasis and orchestrating...
3.
Weidner P, Saar D, Sohn M, Schroeder T, Yu Y, Zollner F, et al.
Cancer Lett
. 2024 Mar;
588:216783.
PMID: 38462034
Inhibition of K-RAS effectors like B-RAF or MEK1/2 is accompanied by treatment resistance in cancer patients via re-activation of PI3K and Wnt signaling. We hypothesized that myotubularin-related-protein-7 (MTMR7), which inhibits...
4.
Ahmed H, Wallimann R, Gisler L, Elghazawy N, Gruber S, Keller C, et al.
ACS Chem Neurosci
. 2023 Dec;
14(24):4323-4334.
PMID: 38060344
The -methyl-d-aspartate receptor (NMDAR) subtype 2B (GluN1/2B) is implicated in various neuropathologies. Given the lack of a validated radiofluorinated positron emission tomography (PET) probe for the imaging of GluN1/2B receptors,...
5.
Korff M, Chaudhary A, Li Y, Zhou X, Zhao C, Rong J, et al.
J Med Chem
. 2023 Nov;
66(23):16018-16031.
PMID: 37979148
GluN2B subunit-containing methyl-d-aspartate (NMDA) receptors have been implicated in various neurological disorders. Nonetheless, a validated fluorine-18 labeled positron emission tomography (PET) ligand for GluN2B imaging in the living human brain...
6.
Kroll S, Hulka L, Kexel A, Vonmoos M, Preller K, Treyer V, et al.
Transl Psychiatry
. 2023 Oct;
13(1):325.
PMID: 37857616
Animal models indicate that the endocannabinoid system (ECS) plays a modulatory role in stress and reward processing, both crucially impaired in addictive disorders. Preclinical findings showed endocannabinoid-modulated synaptic plasticity in...
7.
Haider A, Wang L, Gobbi L, Li Y, Chaudhary A, Zhou X, et al.
ACS Chem Neurosci
. 2023 Oct;
14(20):3752-3760.
PMID: 37788055
The cannabinoid type 2 receptor (CB2) has been implicated in a variety of central and peripheral inflammatory diseases, prompting significant interest in the development of CB2-targeted diagnostic and therapeutic agents....
8.
Ritter N, Disse P, Aymanns I, Mucher L, Schreiber J, Brenker C, et al.
Mol Neurobiol
. 2023 Aug;
60(12):7238-7252.
PMID: 37542648
N-Methyl-D-aspartate receptors (NMDARs) composed of different splice variants display distinct pH sensitivities and are crucial for learning and memory, as well as for inflammatory or injury processes. Dysregulation of the...
9.
Korff M, Chaudhary A, Li Y, Zhou X, Zhao C, Rong J, et al.
Res Sq
. 2023 Feb;
PMID: 36747738
GluN2B subunit-containing -methyl-d-aspartate (NMDA) receptors have been implicated in various neurological disorders. Nonetheless, a validated fluorine-18 labeled positron emission tomography (PET) ligand for GluN2B imaging in the living human brain...
10.
Kecheliev V, Spinelli F, Herde A, Haider A, Haider A, Mu L, et al.
Front Aging Neurosci
. 2022 Oct;
14:1018610.
PMID: 36248003
Neuroinflammation plays an important role in the pathophysiology of Alzheimer's disease. The cannabinoid type 2 receptor (CBR) is an emerging target for neuroinflammation and therapeutics of Alzheimer's disease. Here, we...